Physician profile
Thomas E Brooks
NPI 1023014917
$719.93
in general payments reported to CMS, 2019-2025
11 companies · $27.31 in 2025
The $27.31 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $15.79 · 2021: $168 · 2022: $166 · 2025: $27.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $27.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $27.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $321.81 | 2019-2022 | |
| Horizon Therapeutics Plc | $136.09 | 2019-2021 | |
| Smith+Nephew, INC. | $86.55 | 2019 | |
| Melinta Therapeutics, LLC | $59.35 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $27.31 | 2025 | |
| Intuitive Surgical, INC. | $23.33 | 2019 | |
| Kerecis Limited | $16.49 | 2019 | |
| Sebela Pharmaceuticals INC. | $15.60 | 2019 | |
| Amniox Medical, INC. | $12.80 | 2020 | |
| Grt US Holding, INC. | $10.89 | 2022 | |
| Aroa Biosurgery Incorporated | $9.71 | 2019-2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.